335 related articles for article (PubMed ID: 17037262)
21. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.
Thall PF; Herrick RC; Nguyen HQ; Venier JJ; Norris JC
Clin Trials; 2014 Dec; 11(6):657-66. PubMed ID: 25179541
[TBL] [Abstract][Full Text] [Related]
22. A Bayesian design and analysis for dose-response using informative prior information.
Smith MK; Marshall S
J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
[TBL] [Abstract][Full Text] [Related]
23. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
24. Continuous Bayesian adaptive randomization based on event times with covariates.
Cheung YK; Inoue LY; Wathen JK; Thall PF
Stat Med; 2006 Jan; 25(1):55-70. PubMed ID: 16025549
[TBL] [Abstract][Full Text] [Related]
25. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
26. A robust Bayesian dose-finding design for phase I/II clinical trials.
Liu S; Johnson VE
Biostatistics; 2016 Apr; 17(2):249-63. PubMed ID: 26486139
[TBL] [Abstract][Full Text] [Related]
27. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
Thomas N
J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
[TBL] [Abstract][Full Text] [Related]
28. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
29. A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.
Wang Z; Zhang J; Xia T; He R; Yan F
J Biopharm Stat; 2024 Jul; 34(4):582-595. PubMed ID: 37461311
[TBL] [Abstract][Full Text] [Related]
30. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.
Lin R; Thall PF; Yuan Y
Biometrics; 2020 Mar; 76(1):304-315. PubMed ID: 31273750
[TBL] [Abstract][Full Text] [Related]
31. A two-dimensional search algorithm for dose-finding trials of two agents.
Lee BL; Fan SK
J Biopharm Stat; 2012; 22(4):802-18. PubMed ID: 22651116
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
33. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
34. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
Braun TM; Thall PF; Nguyen H; de Lima M
Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
[TBL] [Abstract][Full Text] [Related]
35. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
Potter DM
J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
[TBL] [Abstract][Full Text] [Related]
36. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
Guo B; Yuan Y
Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
[TBL] [Abstract][Full Text] [Related]
38. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
39. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
40. Adaptive dose insertion in early phase clinical trials.
Hu B; Bekele BN; Ji Y
Clin Trials; 2013 Apr; 10(2):216-24. PubMed ID: 20819841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
